Focusing on DNA Vaccines in 2023

A biotechnology company focused on developing and commercializing DNA medicines today announced it has strategically redirected resources to advance DNA vaccine candidates.

INOVIO Inc. reconfirmed on January 31, 2023, its focus on treating Recurrent Respiratory Papillomatosis, such as the INO-3107 vaccine candidate.

"Today's announcement is a reflection of measured efforts INOVIO has undertaken to assess the portfolio and prioritize those programs with the greatest benefit for patients and commercial potential," said INOVIO's President and CEO, Dr. Jacqueline Shea, in a related press release.

"This decision followed thoughtful consideration and thorough diligence to position the organization better and ultimately realize the potential of DNA medicines."

INOVIO's lead programs include its treatments for HPV-associated diseases, such as INO-3107 and VGX-3100 for cervical high-grade squamous intraepithelial lesions.

The data readouts for INOVIO's Phase 3 REVEAL2 trial for VGX-3100 and the second cohort from the Phase 1/2 trial for INO-3107 are expected to be announced in the first quarter 2023.

INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.

Note: This news article is not paid content.